Associations - AKT inhibitor

BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	BCL2 expression + MYC expression	Diffuse Large B Cell Lymphoma	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1	chidamide Sensitive: A1 - Approval chidamide Sensitive : A1
No biomarker	Tenosynovial Giant Cell Tumor	No biomarker	Tenosynovial Giant Cell Tumor	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1	pexidartinib Sensitive: A1 - Approval pexidartinib Sensitive : A1
PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	PIK3CA mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + HR positive	HER2 Negative Breast Cancer	AKT1 mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN mutation + HR positive	HER2 Negative Breast Cancer	PTEN mutation + HR positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
PTEN deletion + ER positive	HER2 Negative Breast Cancer	PTEN deletion + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
AKT1 mutation + ER positive	HER2 Negative Breast Cancer	AKT1 mutation + ER positive	HER2 Negative Breast Cancer	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1	capivasertib Sensitive: A1 - Approval capivasertib Sensitive : A1
No biomarker	Glioblastoma	No biomarker	Glioblastoma	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B	enzastaurin Sensitive: B - Late Trials enzastaurin Sensitive : B
AKT1 mutation	Triple Negative Breast Cancer	AKT1 mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN mutation	Triple Negative Breast Cancer	PTEN mutation	Triple Negative Breast Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Triple Negative Breast Cancer	PIK3CA mutation	Triple Negative Breast Cancer	RG7440 Resistant: B - Late Trials RG7440 Resistant : B	RG7440 Resistant: B - Late Trials RG7440 Resistant : B
H3.3K27M	Glioma	H3.3K27M	Glioma	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B	ONC201 Sensitive: B - Late Trials ONC201 Sensitive : B
No biomarker	Glioblastoma	No biomarker	Glioblastoma	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	chidamide Sensitive: B - Late Trials chidamide Sensitive : B	chidamide Sensitive: B - Late Trials chidamide Sensitive : B
PTEN deletion	Prostate Cancer	PTEN deletion	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PTEN negative	Prostate Cancer	PTEN negative	Prostate Cancer	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B	RG7440 Sensitive: B - Late Trials RG7440 Sensitive : B
PIK3CA mutation	Solid Tumor	PIK3CA mutation	Solid Tumor	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B	GDC-0084 Sensitive: B - Late Trials GDC-0084 Sensitive : B
AKT1 mutation + ER positive	Breast Cancer	AKT1 mutation + ER positive	Breast Cancer	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1	capivasertib Sensitive: C1 - Off-label capivasertib Sensitive : C1
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PTEN-L	Triple Negative Breast Cancer	PTEN-L	Triple Negative Breast Cancer	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2	pexidartinib Sensitive: C2 – Inclusion Criteria pexidartinib Sensitive : C2
BRCA2 mutation	Prostate Cancer	BRCA2 mutation	Prostate Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
BRCA1 mutation	Prostate Cancer	BRCA1 mutation	Prostate Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PIK3CA mutation	Gastric Cancer	PIK3CA mutation	Gastric Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2	olaparib + capivasertib Sensitive: C2 – Inclusion Criteria olaparib + capivasertib Sensitive : C2
PTEN mutation	Estrogen Receptor Positive Breast Cancer	PTEN mutation	Estrogen Receptor Positive Breast Cancer	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2	capivasertib Sensitive: C2 – Inclusion Criteria capivasertib Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	LY2780301 Sensitive: C2 – Inclusion Criteria LY2780301 Sensitive : C2	LY2780301 Sensitive: C2 – Inclusion Criteria LY2780301 Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	MK-2206 Sensitive: C2 – Inclusion Criteria MK-2206 Sensitive : C2	MK-2206 Sensitive: C2 – Inclusion Criteria MK-2206 Sensitive : C2
ALK positive	Peripheral T-cell Lymphoma	ALK positive	Peripheral T-cell Lymphoma	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2	chidamide Sensitive: C2 – Inclusion Criteria chidamide Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2	RG7440 Sensitive: C2 – Inclusion Criteria RG7440 Sensitive : C2

AKT inhibitor

AKT inhibitor

Associations(169)

Associations
(169)